全文获取类型
收费全文 | 7887篇 |
免费 | 303篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 157篇 |
妇产科学 | 123篇 |
基础医学 | 1186篇 |
口腔科学 | 122篇 |
临床医学 | 450篇 |
内科学 | 1773篇 |
皮肤病学 | 107篇 |
神经病学 | 742篇 |
特种医学 | 326篇 |
外科学 | 1032篇 |
综合类 | 34篇 |
预防医学 | 264篇 |
眼科学 | 99篇 |
药学 | 597篇 |
中国医学 | 37篇 |
肿瘤学 | 1096篇 |
出版年
2023年 | 27篇 |
2022年 | 65篇 |
2021年 | 101篇 |
2020年 | 68篇 |
2019年 | 85篇 |
2018年 | 109篇 |
2017年 | 104篇 |
2016年 | 101篇 |
2015年 | 117篇 |
2014年 | 146篇 |
2013年 | 224篇 |
2012年 | 365篇 |
2011年 | 382篇 |
2010年 | 216篇 |
2009年 | 203篇 |
2008年 | 357篇 |
2007年 | 389篇 |
2006年 | 413篇 |
2005年 | 425篇 |
2004年 | 472篇 |
2003年 | 455篇 |
2002年 | 437篇 |
2001年 | 189篇 |
2000年 | 185篇 |
1999年 | 200篇 |
1998年 | 165篇 |
1997年 | 119篇 |
1996年 | 101篇 |
1995年 | 91篇 |
1994年 | 96篇 |
1993年 | 116篇 |
1992年 | 164篇 |
1991年 | 149篇 |
1990年 | 153篇 |
1989年 | 172篇 |
1988年 | 139篇 |
1987年 | 122篇 |
1986年 | 110篇 |
1985年 | 87篇 |
1984年 | 81篇 |
1983年 | 77篇 |
1982年 | 32篇 |
1981年 | 36篇 |
1980年 | 36篇 |
1979年 | 38篇 |
1978年 | 37篇 |
1977年 | 41篇 |
1976年 | 23篇 |
1975年 | 22篇 |
1974年 | 27篇 |
排序方式: 共有8217条查询结果,搜索用时 15 毫秒
1.
Kensuke Kudou Hiroshi Saeki Yuichiro Nakashima Shun Sasaki Tomoko Jogo Kosuke Hirose Qingjiang Hu Yasuo Tsuda Koichi Kimura Ryota Nakanishi Nobuhide Kubo Koji Ando Eiji Oki Tetsuo Ikeda Yoshihiko Maehara 《American journal of surgery》2019,217(4):757-763
Background
There were few studies assessed the postoperative sarcopenia in patients with cancers. The objective of present study was to assess whether postoperative development of sarcopenia could predict a poor prognosis in patients with adenocarcinoma of esophagogastric junction, (AEG) and upper gastric cancer (UGC).Methods
Patients with AEG and UGC who were judged as non-sarcopenic before surgery were reassessed the presence of postoperative development of sarcopenia 6 months after surgery. Patients were divided into the development group or non-development group, and clinicopathological factors and prognosis between these two groups were analyzed.Results
The 5-year overall survival rates were significantly poorer in the development group than non-development group (68.0% vs. 92.6%, P?=?0.0118). Multivariate analyses showed that postoperative development of sarcopenia was an independent prognostic factor for poor overall survival (P?=?0.0237).Conclusions
Postoperative development of sarcopenia was associated with a poor prognosis in patients with AEG and UGC. 相似文献2.
3.
Hiroki Koshimichi Yoshiyuki Tsuda Toru Ishibashi Toshihiro Wajima 《Journal of pharmaceutical sciences》2019,108(5):1896-1904
Baloxavir marboxil, a prodrug that is metabolized to baloxavir acid, suppresses viral replication by inhibiting cap-dependent endonuclease. Our aim is to characterize its pharmacokinetics and exposure-response relationships. Population pharmacokinetic analysis of the baloxavir acid was performed using 8310 plasma concentration data points from 1109 subjects. Exposure-response analyses were performed regarding the time to alleviation of symptoms and the reduction in the influenza virus titer. A 2-compartment model with first-order absorption and lag time well described the plasma concentration data for baloxavir acid, and body weight and race were found to be the most important factors influencing the clearance and distribution volume. A dose regimen based on the body weight (40 mg for patients weighing <80 kg and 80 mg for patients weighing ≥80 kg) could provide sufficient exposures for expecting efficacy irrespective of body weight or race; however, the exposures were dependent on the body weight and race. Exposure-response analyses suggested that the reduction in the influenza virus titer was greater in any exposure-based groups in baloxavir marboxil treatment than in the oseltamivir phosphate treatment and placebo groups. In conclusion, the population pharmacokinetic model and exposure-response relationships would be useful for understanding the pharmacokinetic and pharmacodynamic characteristics of baloxavir acid. 相似文献
4.
5.
6.
7.
8.
T. Akatsu T. Murakami K. Ono M. Nishikawa E. Tsuda S.-I. Mochizuki N. Fujise K. Higashio K. Motoyoshi M. Yamamoto N. Nagata 《BONE》1998,23(6):495-498
Osteoclastogenesis inhibitory factor (OCIF) is a novel secreted protein that inhibits osteoclastogenesis both in vitro and in vivo. In this study, we examined the effects of OCIF on serum calcium (Ca) concentrations in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. In normal mice, a single intraperitoneal injection of OCIF reduced serum Ca levels in a dose-dependent manner. Significant decrease in serum Ca (by 1.6 ± 0.3 mg/dL, n = 5) was observed 2 h after the injection of OCIF at 20 mg/kg and the hypocalcemic effect continued for up to 12 h. Serum phosphate (Pi) concentrations also decreased in response to OCIF. Urinary excretion of Ca, Pi, and creatinine did not change significantly after injection of OCIF or vehicle. In hypercalcemic, tumor-bearing nude mice, a single intraperitoneal injection of OCIF at 20 mg/kg resulted in a dramatic decrease in serum Ca (maximal decrease 2.8 ± 0.37 mg/dL, n = 11), which continued for up to 24 h. The results suggest that OCIF decreased serum Ca through its inhibitory effect on bone resorption. Furthermore, it is suggested that OCIF has therapeutic potential for the treatment of hypercalcemic conditions such as malignancy-associated hypercalcemia. 相似文献
9.
10.